Cartesian Therapeutics Inc (RNAC)
15.77
-8.50
(-35.02%)
USD |
NASDAQ |
Jul 02, 16:00
15.89
+0.12
(+0.76%)
After-Hours: 07:56
Cartesian Therapeutics Cash from Investing (Quarterly): -0.602M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -0.602M |
| December 31, 2023 | 6.497M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | -0.012M |
| March 31, 2023 | 28.12M |
| December 31, 2022 | 5.489M |
| September 30, 2022 | -29.94M |
| June 30, 2022 | -0.099M |
| March 31, 2022 | 9.545M |
| December 31, 2021 | 9.722M |
| September 30, 2021 | -1.802M |
| June 30, 2021 | -2.615M |
| March 31, 2021 | -22.44M |
| December 31, 2020 | -0.166M |
| September 30, 2020 | -0.286M |
| June 30, 2020 | -0.154M |
| March 31, 2020 | -0.135M |
| December 31, 2019 | -0.009M |
| September 30, 2019 | 11.51M |
| Date | Value |
|---|---|
| June 30, 2019 | 4.845M |
| March 31, 2019 | -16.12M |
| December 31, 2018 | -0.374M |
| September 30, 2018 | 6.016M |
| June 30, 2018 | 18.68M |
| March 31, 2018 | 0.945M |
| December 31, 2017 | 6.107M |
| September 30, 2017 | -2.371M |
| June 30, 2017 | 10.70M |
| March 31, 2017 | -16.53M |
| December 31, 2016 | -5.204M |
| September 30, 2016 | -20.21M |
| June 30, 2016 | 6.869M |
| March 31, 2016 | -3.555M |
| December 31, 2015 | -2.909M |
| September 30, 2015 | -1.217M |
| June 30, 2015 | -0.43M |
| March 31, 2015 | -0.123M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-29.94M
Minimum
Sep 2022
28.12M
Maximum
Mar 2023
0.6646M
Average
-0.099M
Median
Jun 2022
Cash from Investing (Quarterly) Benchmarks
| Marinus Pharmaceuticals Inc | 20.88M |
| Adial Pharmaceuticals Inc | -- |
| Poseida Therapeutics Inc | 24.00M |
| Viracta Therapeutics Inc | 14.19M |
| Biomea Fusion Inc | -0.035M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -15.92M |
| Cash from Financing (Quarterly) | 43.03M |
| Free Cash Flow | -58.99M |
| Free Cash Flow Per Share (Quarterly) | -3.051 |
| Free Cash Flow to Equity (Quarterly) | -16.52M |
| Free Cash Flow Yield | -71.31% |